References
- Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. The Journal of clinical psychiatry, 67 Suppl 6, 16–22.
- Berlim, M. T., & Turecki, G. (2007). Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 52(1), 46–54.
https://doi.org/10.1177/070674370705200108 - Serafini, G., Adavastro, G., Canepa, G., Capobianco, L., Conigliaro, C., Pittaluga, F., Murri, M. B., Valchera, A., De Berardis, D., Pompili, M., Lindqvist, D., Brundin, L., & Amore, M. (2017). Abnormalities in Kynurenine Pathway Metabolism in Treatment-Resistant Depression and Suicidality: A Systematic Review. CNS & neurological disorders drug targets, 16(4), 440–453.
https://doi.org/10.2174/1871527316666170413110605 - Czarnecka, K., Chuchmacz, J., Wójtowicz, P., & Szymański, P. (2021). Memantine in neurological disorders - schizophrenia and depression. Journal of molecular medicine (Berlin, Germany), 99(3), 327–334.
https://doi.org/10.1007/s00109-020-01982-z - Réus, G. Z., de Moura, A. B., Borba, L. A., Abelaira, H. M., & Quevedo, J. (2019). Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models. Molecular neuropsychiatry, 5(4), 178–189.
https://doi.org/10.1159/000500324 - Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological psychiatry, 47(4), 351–354.
https://doi.org/10.1016/s0006-3223(99)00230-9 - Garcia, L. S., Comim, C. M., Valvassori, S. S., Réus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., & Quevedo, J. (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Progress in neuro-psychopharmacology & biological psychiatry, 32(1), 140–144.
https://doi.org/10.1016/j.pnpbp.2007.07.027 .. - Liebrenz, M., Borgeat, A., Leisinger, R., & Stohler, R. (2007). Intravenous ketamine therapy in a patient with treatment-resistant major depression. Swiss medical weekly, 137(15-16), 234–236.
- Strzelecki, D., Tabaszewska, A., Barszcz, Z., Józefowicz, O., Kropiwnicki, P., & Rabe-Jabłońska, J. (2013). A 10-week memantine treatment in bipolar depression: a case report. Focus on depressive symptomatology, cognitive parameters and quality of life. Psychiatry investigation, 10(4), 421–424.
https://doi.org/10.4306/pi.2013.10.4.421 - Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biological psychiatry, 47(4), 351–354.
https://doi.org/10.1016/s0006-3223(99)00230-9 - Réus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F., Roesler, R., & Quevedo, J. (2010). Neurochemical and behavioral effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression?. Brain research bulletin, 81(6), 585–589.
https://doi.org/10.1016/j.brainresbull.2009.11.013 - Onogi, H., Ishigaki, S., Nakagawasai, O., Arai-Kato, Y., Arai, Y., Watanabe, H., Miyamoto, A., Tan-no, K., & Tadano, T. (2009). Influence of memantine on brain monoaminergic neurotransmission parameters in mice: neurochemical and behavioral study. Biological & pharmaceutical bulletin, 32(5), 850–855.
https://doi.org/10.1248/bpb.32.850 - Ferguson, J. M., & Shingleton, R. N. (2007). An open-label, flexible-dose study of memantine in major depressive disorder. Clinical neuropharmacology, 30(3), 136–144.
https://doi.org/10.1097/WNF.0b013e3180314ae7 - Zarate, C. A., Jr, Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. The American journal of psychiatry, 163(1), 153–155.
https://doi.org/10.1176/appi.ajp.163.1.153